PCSK9 and Alzheimer disease: Consistently, in a recent Mendelian randomization analysis, PCSK9 loss-of-function mutations were not associated to a rise in the risk of AD [Hazard Ratio (HR) = 0.50; p = 0.37; Benn et al., 2017].